- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01437033
Breath Test for Chemicals (Volatile Organic Compounds)
A Pilot Study of a Breath Test for Assessment of Volatile Organic Compounds
Background:
- Some types of cancer, like cancer of the esophagus, are difficult to detect at an early stage. A possible detection method involves collecting breath samples to look for chemicals that may be signs of cancer. However, more research is needed to determine how different chemicals appear in different breath samples. This study will involve healthy volunteers.
Objectives:
- To study chemicals appearing in breath samples of healthy volunteers.
Eligibility:
- Healthy volunteers between 30 and 60 years of age.
Design:
- Participants will fast overnight (midnight to morning) and then provide two breath samples taken 5 minutes apart.
- Breath samples will be collected on days 1, 49, and 98 of the study
Study Overview
Status
Conditions
Detailed Description
Background:
Although breath tests are common for specific uses where the biomarker is highly concentrated (e .g. alcohol, urea for Helicobacter prylori infection), lower concentration compounds in the breath can also provide information on exogenous exposures and endogenous metabolic processes.
Employing standardized collection techniques and high sensitivity measurement technologies have shown that breath profiles can accurately identify people with diseases such as breast cancer and lung cancer.
Breath profiling technologies have great potential as non-invasive tools for diagnosis and risk stratification of precancerous disease as well as elucidation of the causes of cancer.
Prior to using breath profiles for these purposes it is essential to assess how much of the breath profile and which parts of the breath profile are relatively stable over a period of time.
Objectives:
The primary objective of this pilot study is to assess the intra-individual variability of breath profiles sampled over a period of 98 days.
Eligibility:
DCEG volunteers aged 30-60 years, inclusive.
Design:
Pilot study.
Five DCEG volunteers will be enrolled for this study.
We will assess breath profiles sampled in duplicate at three time periods (days 1, 49 and 98).
We will calculate a coefficients of variation (CV) to determine the proportion and parts of the breath profile which have values less than 10% when collected on the same day,49 days apart, and 98 days apart.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Maryland
-
Bethesda, Maryland, United States, 20892
- National Cancer Institute (NCI), 9000 Rockville Pike
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
- INCLUSION CRITERIA:
DCEG volunteers aged 30-60 years, inclusive.
EXCLUSION CRITERIA:
Aged less than 30 years. Aged 61 years or older. Individuals who identify themselves to be in any one of the following categories over the next 4 month period:
- Plan to initial a large change in their daily amount of physical activity
- Plan to make large changes to their diet (reduce caloric intake, become a vegetarian etc)
- May possibly move away from the area for a new job, sabbatical, retirement etc
- Plan to attempt to become pregnant
- Have limited availability for any reason including prolonged vacation or business travel
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Statistics of robustness (CV, ICCs)
Time Frame: 98 days
|
98 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Michael B Cook, M.D., National Cancer Institute (NCI)
Publications and helpful links
General Publications
- Cook MB, Dawsey SM, Diaw L, Blaser MJ, Perez-Perez GI, Abnet CC, Taylor PR, Albanes D, Virtamo J, Kamangar F. Serum pepsinogens and Helicobacter pylori in relation to the risk of esophageal squamous cell carcinoma in the alpha-tocopherol, beta-carotene cancer prevention study. Cancer Epidemiol Biomarkers Prev. 2010 Aug;19(8):1966-75. doi: 10.1158/1055-9965.EPI-10-0270. Epub 2010 Jul 20.
- Vizcaino AP, Moreno V, Lambert R, Parkin DM. Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973-1995. Int J Cancer. 2002 Jun 20;99(6):860-8. doi: 10.1002/ijc.10427. Erratum In: Int J Cancer 2002 Oct 20;101(6):599.
- Perera FP. Cancer: the big questions to address in coming years. Cancer Epidemiol Biomarkers Prev. 2011 Apr;20(4):571-3. doi: 10.1158/1055-9965.EPI-11-0184. No abstract available.
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 999911243
- 11-C-N243
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Human Volunteers
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
PfizerCompleted
-
Bispebjerg HospitalCompleted
-
PfizerCompletedHuman VolunteersUnited States
-
Tibotec Pharmaceuticals, IrelandCompleted
-
Universal EnterprisesUnknown
-
PfizerCompletedHuman VolunteersSingapore